You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 28, 2024

CLINICAL TRIALS PROFILE FOR VADASTUXIMAB TALIRINE

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for Vadastuximab Talirine

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT01902329 ↗	A Safety Study of SGN-CD33A in AML Patients	Completed	Seagen Inc.	Phase 1	This study will examine the safety profile of vadastuximab talirine (SGN-CD33A) administered as a single agent and in combination with a hypomethylating agent (HMA). The main purpose of the study is to find the maximum tolerated dose (MTD, which is the highest dose that does not cause unacceptable side effects) of SGN-CD33A in patients with acute myeloid leukemia (AML). The MTD will be determined by observing the dose-limiting toxicities (the side effects that prevent further increases in dose) of SGN-CD33A. In addition, the pharmacokinetic profile and anti-leukemia activity of SGN-CD33A will be assessed.
NCT01902329 ↗	A Safety Study of SGN-CD33A in AML Patients	Completed	Seattle Genetics, Inc.	Phase 1	This study will examine the safety profile of vadastuximab talirine (SGN-CD33A) administered as a single agent and in combination with a hypomethylating agent (HMA). The main purpose of the study is to find the maximum tolerated dose (MTD, which is the highest dose that does not cause unacceptable side effects) of SGN-CD33A in patients with acute myeloid leukemia (AML). The MTD will be determined by observing the dose-limiting toxicities (the side effects that prevent further increases in dose) of SGN-CD33A. In addition, the pharmacokinetic profile and anti-leukemia activity of SGN-CD33A will be assessed.
NCT02326584 ↗	A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML	Completed	Seagen Inc.	Phase 1	This study will examine the safety profile of vadastuximab talirine (SGN-CD33A) by itself (monotherapy) or in combination with other standard treatments. The main purpose of this study is to find the best dose and schedule for SGN-CD33A when given in combination with standard induction treatment, in combination with standard consolidation treatment, or by itself for maintenance treatment. This will be determined by observing the dose-limiting toxicities (the side effects that prevent further increases in dose) of SGN-CD33A. In addition, the pharmacokinetic profile and anti-leukemic activity of the study treatment will be assessed.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for Vadastuximab Talirine

Condition Name

Chart
Table

Condition Name for
Intervention	Trials
Acute Myeloid Leukemia	4
Acute Myelogenous Leukemia	2
Acute Promyelocytic Leukemia	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for
Intervention	Trials
Leukemia, Myeloid, Acute	4
Leukemia, Myeloid	4
Leukemia	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Vadastuximab Talirine

Trials by Country

Map
Table

Trials by Country for
Location	Trials
United States	81
Taiwan	1
Australia	1
Czechia	1
Hungary	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for
Location	Trials
Washington	5
Texas	5
California	5
Illinois	4
Colorado	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Vadastuximab Talirine

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 3	1
Phase 1/Phase 2	2
Phase 1	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for
Clinical Trial Phase	Trials
Terminated	3
Completed	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Vadastuximab Talirine

Sponsor Name

Chart
Table

Sponsor Name for
Sponsor	Trials
Seagen Inc.	5
Seattle Genetics, Inc.	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for
Sponsor	Trials
Industry	10
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.